The Leukapheresis Devices Market, estimated at USD 35.0 Mn in 2025, is expected to exhibit a CAGR of 7.9% and reach USD 59.6 Mn by 2032.
The industry is witnessing significant growth driven by rising demand for advanced, reliable, and cost-effective medical devices across diagnostic, therapeutic, and monitoring applications. Rapid advancements in device design, digital health integration, and adoption of minimally invasive technologies are reshaping the competitive landscape. Furthermore, supportive regulatory frameworks, increasing healthcare investments, and the growing focus on patient-centric care are expected to create new growth avenues for market players.
Major players in the market are focused on inorganic strategies such as aquisition is expected to drive the market in forecast period. For instance, In December 2025, Asahi Kasei Medical Co., Ltd., pharmaceutical corporation, announced that it has (via a wholly owned subsidiary) fully acquired Bionique Testing Laboratories LLC (Bionique), a leader in mycoplasma testing services for the biotherapeutics and life-sciences industries.The acquisition expands Asahi Kasei Medical’s biosafety contract testing business, launched with the acquisition of viral safety testing services provider ViruSure in Austria. It also creates new business growth opportunities, both geographically and in terms of a broader range of testing services offered. Bionique’s ongoing delivery of world-class mycoplasma testing services will enhance Asahi Kasei Medical’s ability to dependably supply innovative yet exceptionally reliable bioprocess consumables, equipment and related scientific support, and biosafety testing services, to help biotherapeutics manufacturers safely and efficiently produce medicines
Global Leukapheresis Devices Market– Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2025 as "coronavirus disease 2025" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms, and financial markets. Due to the lockdown, several countries, such as India, China, Brazil, and others faced problems with regard to the transportation of drugs from one place to another.
COVID-19 had a positive impact on the global leukapheresis devices market. For instance, in August 2025, the Drugs Controller General of India (DGCI), approved the use of an apheresis machine to extract blood plasma in Goa for critically ill COVID-19 patients. Furthermore, in April 2025, Terumo BCT Inc. develops and supply blood component and cellular technologies and Marker Therapeutics AG is dedicated to the development and commercialization of next-generation T cell-based immunotherapies for patients, received the U.S. Food and Drug Administration approval for the Emergency Use Authorization (EUA) of Terumo BCT’s Spectra Optia Apheresis System combined with Marker Therapeutics’ D2000 Adsorption Cartridge to treat COVID-19 patients aged 18 years or above. Hence, such approvals would increase the market growth.
Global Leukapheresis Devices Market Market: Key Developments
In October 2025, Turtle Shell Technologies Pvt Ltd, a contactless remote patient monitoring (RPM) company in India, launched an ambulatory electrocardiogram (ECG) patch to monitor patients with blood disease.
On April 17, 2025, GE HealthCare, a healthcare technology and diagnostics company, showcased its growing portfolio of digital platforms and solutions at the Health Information and Management Systems Society, Inc. (HIMSS) Global Health Conference and Exhibition in Chicago.
In April 2025, Wipro GE Healthcare, a healthcare technology and diagnostics company, announced the launch of its new manufacturing facility in Bengaluru, India, under the Government’s Production Linked Incentive (PLI) Scheme. Set up with an investment of Rs 100 crore, the new plant Wipro GE Medical Device Manufacturing factory (MDM) is one of the 15 medical device manufacturers approved under the scheme.
In December 2025, Asahi Kasei Medical Co., Ltd., a pharmaceutical corporation, announced that it has (via a wholly owned subsidiary) fully acquired Bionique Testing Laboratories LLC (Bionique), a leader in mycoplasma testing services for the biotherapeutics and life-sciences industries.
Browse 36 Market Data Tables and 33 Figures spread through 180 Pages and in-depth TOC on “Global Leukapheresis Devices Market Market”- Forecast to 2032, Global Leukapheresis Devices Market Market, by Device Type (Apheresis Devices, Leukapheresis Columns & Cell Separators, Leukoreduction Filters, and Leukapheresis Disposables), By Application (Research Applications and Therapeutic Applications), by End User (Hospitals, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Blood Component Providers, and Blood Centers), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/leukapheresis-devices-market-4142
Key Takeaways of the Global Leukapheresis Devices Market Market:
- The global Leukapheresis Devices Market market is expected to exhibit a CAGR of 7.9% during the forecast period. Market players are involved in deploying strategic initiatives, which include product launches and expansion of distribution networks. For instance, in November 2025, Royal Philips, a health technology company improving people's health and well-being through meaningful innovation, signed an agreement to acquire Cardiologs, a France-based medical technology company focused on cardiac diagnostics using artificial intelligence (AI) and cloud technology. The acquisition strengthens Philips blood monitoring and diagnostics offering with innovative software technology, electrocardiogram (ECG) analysis, and reporting services.
- Among Device type, the apheresis devices equipment is anticipated to hold a significant share in the global leukapheresis devices market during the forecast period. This is due to its wide range of advantages, such as the compact size of the device, higher accuracy, longer life, and less requirement of power, educate to learn correct inhalation technique. For instance, in June 2025, Lupin Limited, an multinational pharmaceutical company based in India, announced the launch of its Digital blood Educator platform to help patients to learn correct cardiac techniques for better management of blood disease.
- Among region, North America is expected to hold a large market share in the leukapheresis market due to the rising geriatric population and increasing prevalence and incidence of leukemia in the region. According to the North American Association of Central Cancer Registries (NAACCR), in 2025, approximately 60,650 people are expected to be diagnosed with leukemia.
- Major players operating in the Leukapheresis Devices Market market are include Asahi Kasei Medical Co. Ltd., Haemonetics Corporation, Terumo BCT Inc., STEMCELL Technologies Inc., Fresenius SE & Co. KGaA, BioIVT, Grifols, S.A, , HemaCare, B. Braun Melsungen AG, Caltag Medsystems Limited, AllCells, StemExpress, PPA, Cellero, Precision for Medicine, Inc., The Intelligent Tissue Group Lonza, BioIVT, Lmb Technologie GmbH, Kaneka Medical Europe N.V. and Key Biologics, LLC.
Contact Us